Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017;16(17):1566-1567.
doi: 10.1080/15384101.2017.1355171. Epub 2017 Jul 27.

Identification of more potent imipridones, a new class of anti-cancer agents

Andrew S Chi  1
Affiliations
Comment

Identification of more potent imipridones, a new class of anti-cancer agents

Andrew S Chi. Cell Cycle. 2017.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al.. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5:171ra17; PMID:23390247; https://doi.org/10.1126/scitranslmed.3004828 - DOI - PMC - PubMed
    1. Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, et al.. First-in-Human Clinical Trial of Oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 2017; PMID:28331050; https://doi.org/10.1158/1078-0432.CCR-16-2658 - DOI - PMC - PubMed
    1. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017; PMID:28562358; https://doi.org/10.18632/oncotarget.17837 - DOI - PMC - PubMed
    1. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, et al.. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 2016; 7:74380-92; PMID:27602582; https://doi.org/10.18632/oncotarget.11814 - DOI - PMC - PubMed
    1. Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl. 2014; 53:6628-31; PMID:24838721; https://doi.org/10.1002/anie.201402133 - DOI - PubMed

LinkOut - more resources